NOVO — Juni 2025
-
BrightGene Pharmaceutical reported upbeat mid-stage results for its investigational dual GLP-1/GIP agonist BGM0504, demonstrating superior glycaemic control over Novo Nordisk’s GLP-1 agonist Wegovy/Ozempic (semaglutide) in patients with type 2 diabetes, along with significant weight reduction in obese individuals. The data were presented at the American Diabetes Association (ADA) annual meeting. https://firstwordpharma.com/story/5975593
-
Novo-rival har store forventninger til ny vægttabspille https://proinvestor.com/investornyt/1332887/novo-rival-har-store-forventninger-til-ny-vaegttabspille
-
Eli Lilly og Novo Nordisk vil blive førende inden for lægemiddelsalg i 2030, vurderer analyse
Dataanalysevirksomheden Evaluate Pharma forudser, at Eli Lilly vil toppe listen over verdens førende lægemiddelsælgere i 2030, mens Novo Nordisk vil indtage en andenplads.
(medwatch.dk)
-
Hvordan påvirker den geopolitiske uro i Mellemøsten de globale aktiemarkeder? Ugens afsnit af Investeringspodcasten dykker ned i investorernes reaktioner og markedets udvikling.
I dette afsnit får du også:
Seneste nyt om Novo Nordisk: Ny data og afbrudt samarbejde
Indblik i Teslas robottaxi og hvad det kan betyde for aktien https://proinvestor.com/boards/127002 -
Health Rounds: Inhaled insulin as good as injection for children at mealtime - https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-inhaled-insulin-good-injection-children-mealtime-2025-06-25/ Reuters
-
Novo-rival gearer op i Indien https://proinvestor.com/investornyt/1333361/novo-rival-gearer-op-i-indien
-
Novo-rival har lovende resultater med blødermedicin https://proinvestor.com/investornyt/1333420/novo-rival-har-lovende-resultater-med-blodermedicin
-
Novo indgår nyt samarbejde for Wegovy med Weightwatchers i USA https://proinvestor.com/investornyt/1333627/novo-indgar-nyt-samarbejde-for-wegovy-med-weightwatchers-i-usa
-
Altimmune's incretin can't make good on fibrosis improvement promises https://firstwordpharma.com/story/5976630
-
Novo Nordisk har i den forgangne uge igen været et af de helt store samtaleemner på ProInvestor.com. Denne gang er det en droppet aftale med Hims & Hers, der fik aktiekursen til atter at droppe. Efterfulgt af en nyhed, der fik kursen lidt tilbage på sporet, nemlig et samarbejde med Weight Watchers. Så handler denne ugekommentar også om Gubra og udbytte, og om hvorvidt Zealand Pharma burde gøre det samme. Kort video: https://proinvestor.com/boards/127044
-
Novo Nordisk, Eli Lilly: "Skildpadden og Haren" https://proinvestor.com/boards/127050
-
Innovent's Lilly-partnered obesity asset wins approval in China https://firstwordpharma.com/story/5976911
-
Novo Nordisk: Fra darling til investorskepsis på 12 måneder https://proinvestor.com/boards/127061
-
Novo får ny konkurrent på fedmemarkedet i Kina https://proinvestor.com/investornyt/1334510/novo-far-ny-konkurrent-pa-fedmemarkedet-i-kina
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind